

Neurotech
International



Improving Lives

Phase I/II Trial Results Webinar

July 2022

Dr Alexandra Andrews

PhD Neuroscience, BBMed Sci (Hons1st)
Chief Executive Officer

Brian Leedman

BEd, MBA (UWA)
Chairman

Gerald Quigley

B(Pharm)
Non-Executive Director

Disclaimer



IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (Neurotech or Company). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (US Securities Act). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events.

These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

Proprietary information and copyright: This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.

Webinar Agenda - 8 July 2022

15 minute presentation



Dr Alexandra Andrews
CEO




Brian Leedman
Chairman



Gerald Quigley
Non-Executive Director

20 minute live Q & A

Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life.



**Successful Phase I/II
Trial 93% of patients
showed improvement**



**World's first whole
plant extract cannabis
clinical study**



**Exclusive worldwide
licence**



PTC Patents lodged



**Potential for NTI164
to treat neurological
disorders**



**Neurotech's Mente
device & therapy**

Capital Structure

\$0.075

Share price
(as at 1st July 2022)

~\$52M

**Market
capitalisation**

~\$2.33M

Cash at bank*

697M

Share on issue

143M[^]

Options/rights



1. *as at COB 31 March 2022

2. ^Options are comprised at various strike prices between \$0.005 to \$0.09 as at 31 December 2021

What makes NTI164 different?

NTI164

VS

CBD/THC

- ✓ High CBDA
- ✓ Rarer Cannabinoids: CBC, CBDP, CBDB, CBN, CBG
- ✓ Naturally >0.03% THC
- ✓ >4% Terpenes

- ✗ CBDA
- ✗ Rare Cannabinoids
- ✗ Full Plant Extract
- ✗ Patent protected composition



The Program

First in human Phase I/II ASD paediatric study (S8)

Commenced in May 2021 at Monash Children's Hospital led by A/Prof. Michael Fahey

Open label – single group

14 patients from 8 to 17yo, Level II and III Autism Spectrum Disorder

Dose regime assessments

5mg/kg, 10mg/kg, 15mg/kg and 20mg/kg

2,250 Assessment points

Parameters Anxiety, Participation, Irritability, Hyperactivity, Mood and Self-stimulation

NTI164 Phase I/II Trials

Outcomes

93% of patients showed improvement

Global Improvement

64% of patients "much improved"

29% of patients "minimally improved"

7% of patients "no change"

Therapeutic Effect (Efficacy Index)

2 patients Therapeutic Index Score of 2

Vast Improvement complete or near remission of all symptoms

10 patients Therapeutic Index Score of 5 & 6

Decided improvement" – Partial remission of symptoms

No "washout" period

Due to the positive therapeutic effects of NTI164 combined with feedback from parents and clinicians

**NTI164 measures favourably when compared to other recently completed
CBD and/or THC paediatric studies^{1,2}**

¹ Thomas, M. & Frampton, C., (2022) HOPE® 1 demonstrates improvements in Clinical Global Impression (CGI) in patients with Autism Spectrum Disorder. https://zeliratx.com/wp-content/uploads/2022/04/ZEL040-White-Paper_Hope_FA.pdf

² Shani Poleg, et al (2019). Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in Neuro- Psychopharmacology and Biological Psychiatry. <https://www.sciencedirect.com/science/article/abs/pii/S0278584618304445>

NTI164 Phase I/II Trials

NTI164 was well-tolerated

No serious adverse events recorded

Across all doses (5, 10, 15 and 20 mg/kg)

NTI164 shows promise compared to other current treatments

Risperidone

Existing prescribed medications for the treatment of symptoms associated with ASD have untoward side effects including:

- Weight gain,
- Sedation and
- Hormonal imbalance

***Chief Investigator Professor Fahey,
Monash Children's Hospital said,***

“I am very encouraged with these results. We have designed a rigorous study on all fronts to assess the potential application of NTI164 for the treatment of ASD. We are encouraged by the efficacy shown by NTI164 in this trial and we are looking forward to the extension of this trial, in addition to the planned initiation of a Phase II/III trial, to further assess the long-term safety and efficacy of NTI164 with the potential to lead to drug registration.”

Why target Autism Spectrum Disorders (ASD)?

PREVALENCE OF ASD
~1 in 44 children
in the US¹

Market

ASD is a serious
neuro inflammatory
developmental disorder
that impairs the ability to
communicate and interact

- Common symptoms include; behavioural issues, agitation, repetitive movements, inability to focus & compulsive neurological patterns



RISPERIDONE
US\$5.6b²



**US ANNUAL
SALES US\$2.1b³**
Ritalin and Concerta
Active ingredient Methylphenidate

Current Treatment

Huge unmet medical need -
patients need better treatment

- Current drugs have numerous side effects; weight gain, breast tissue development, nausea, dry mouth, anxiety, irritability, insomnia, stomach pain & movement disorders

**TREATMENT
MARKET SIZE
US\$1.85b⁴**

Trials

NTI has completed world first
trial using whole plant (low THC)
medicinal cannabis strain in
children with ASD



Current and Future Opportunities for NTI164

**AUTISM
SPECTRUM
DISORDER**

US\$2.3b¹

Phase I/II completed

Phase II/III due to
commence Q3 2022

**CEREBRAL
PALSY**

US\$4.4b³

by 2030
Future Target

MIGRAINE

US\$1.7b⁵

Future Target

**COMBINATION
THERAPIES**

Prednisone
Diclofenac
& other

**MULTIPLE
SCLEROSIS**

US\$20b²

Preclinical studies in
progress

Future Target

ADHD

\$21b⁴

Future Target

**TRAUMATIC
BRAIN
INJURY**

US\$2.7b⁶

Future Target

Pathways to Commercialisation

The anti-inflammatory properties NTI strains in combination with minimal presence of THC (< 0.3%) provides clear pathways to commercialisation:

Pharmaceutical

- FDA new drug registration
- Huge potential upside
- Partnering/licensing opportunities

Combination

- Fast route to commercialisation via the 505B2 route
- Combination with existing drugs i.e. Prednisone, Diclofenac, Celebrex

**GW Pharmaceuticals US\$7.2B
Acquisition by Jazz Pharmaceuticals¹**

Strong Patent Position

Neurotech has lodged two strategic provisional patent applications with IP Australia to underpin future worldwide commercialisation in Neurological applications and has completed international prior art search.

Composition

Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) and a unique combination of ‘rarer’ cannabinoids:
CBDA, CBC, CBDP, CBDB & CBN


Lodged Oct 2021

Combination

The application, formulation and use of NTI164

Lodged Oct 2021

NTI164 Development Program Timeline



Highly Experienced Executive Team and Board



Dr Alexandra Andrews
CEO

Expertise in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.

Former Director of Operations at NeuroScientific Biopharmaceuticals Ltd.

PhD Neuroscience, BBMed Sci (Hons1st)



Brian Leedman
Chairman

More than 15 years' experience in the biotechnology sector

Co-founder / Director / Chairman of six ASX listed healthcare/ biotechnology companies including: RAP, NGS, NSB, OSL, IMU, ALC

Former Chairman of Ausbiotech (WA)

BEd, MBA (UWA)



Krista Bates
Non-Executive Director

Experienced company director with over 20 years experience in various roles within the Australian capital markets

Core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance

BA(Hons), GradDip(Law), PostGradDip(Law), GAIDC



Prof. Allan Cripps AO
Non-Executive Director

Distinguished academic, clinical scientist and health services leader

Independent Chair of the Children's Health Research Alliance Board and Non- Executive Director at Bard1 (BD1)

Formerly the Pro Vice Chancellor (Health) at Griffith University and currently professor emeritus at Griffith University

PhD, BSc (Hons), FAHSM, FASM, FAIMS, FIBMS, FCHSM, MACID



Mark Davies
Non-Executive Director

More than 20 years' experience in trading, investment banking & providing corporate advice

Specialises in providing corporate advice & capital raising services to emerging companies seeking business development opportunities and funding from the Australian market

Managing Director of 1861 Capital and co-founder of investment banking firm, Cygnet Capital

BCom




Winton Willesse
Non-Executive Director

Experienced company director with over 20 years experience in various roles within the Australian capital markets

Core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance

MCom, FFin, CPA, GAICD, FGIA/FCG



Gerald Quigley
Non-Executive Director


Pharmacist and consumer health commentator.

Leading media health commentator heard each week on television and radio stations across Australia.

Extensive knowledge relating to pharmaceutical/nutraceutical product development, dispensing & marketing in addition to product positioning within the relevant regulatory landscapes (eg. TGA, FDA).

B(Pharm)

Why Invest



**Experienced
board and
management**



**Unique
biopharmaceutical
cannabinoid
platform**



**Clinical
programs
underway
targeting pivotal,
unmet needs**



**Significant
near term
milestones
& newsflow**





Neurotech

International

Contact Details

Dr Alexandra Andrews
CEO

aa@neurotechinternational.com
+61 405 339 788

Media:

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 (0)431 636 033

www.neurotechinternational.com
www.mentetech.com

Neurotech International Limited (ASX:
NTI)